Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
Type:
Grant
Filed:
March 1, 2021
Date of Patent:
April 23, 2024
Assignee:
UNM RAINFOREST INNOVATIONS
Inventors:
Eric R. Prossnitz, Geetanjali Sharma, Matthias Barton, Matthias R. Meyer
Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.
Abstract: The present invention relates to compound of formula (I), wherein R1 is chloro, bromo iodo or a brosylate group. The present invention also relates to methods of making this compound and its use in carrying out organic transformations.
Abstract: An acetylsalicylic acid derivative and an application thereof. The present disclosure relates to the field of chemical pharmaceuticals, and in particular, to a compound shown in formula (I) or pharmaceutically acceptable salts thereof.
Abstract: A N?-({[(5-phenyl-1,3,4-oxadiazol-2-yl)sulfanyl]acetyl}oxy)benzenecarboximidamide compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
October 13, 2023
Date of Patent:
April 16, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: Selective small molecule regulators of GIRK potassium channels are provided, which are effective in treatment of post-traumatic stress disorder and other medical conditions.
Type:
Grant
Filed:
June 11, 2019
Date of Patent:
April 9, 2024
Assignees:
Northeastern University, Indiana University Research and Technology Corporation
Inventors:
Ganeshsingh A. Thakur, Diomedes E. Logothetis, Lucas Cantwell, Yu Xu, Anantha Shekhar
Abstract: Provided is a method for preventing or treating a wound or scar comprising administering to a subject in need thereof a pharmaceutical composition comprising benzbromarone as an active ingredient, wherein benzbromarone inhibits the function of heat shock protein 47 (HSP47), or inhibits the accumulation of collagen by reducing collagen overproduction cells.
Abstract: A crystalline form I of 1,4-BIS[1,2-BENZISOSELENAZOL-3(2H)-one]-butane has characteristic peaks at 2? angles of 6.17±0.20°, 12.28±0.20°, 18.44±0.20°, 25.92±0.20° and 30.95±0.20° by X-ray powder diffraction using Cu-K? radiation.
Abstract: A 1-cyclopropyl-6-fluoro-4-oxo-7-(4-((5-oxo-2-phenyl-4-(quinolin-2-ylmethylene)-4,5-dihydro-1H-imidazol-1-yl)methyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or anti-inflammatory agent.
Type:
Grant
Filed:
September 21, 2023
Date of Patent:
April 2, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: Diphosphate salts of N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine, and crystalline forms thereof, processes for the preparation of the new salt forms; and their use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
April 2, 2024
Assignee:
CRT Pioneer Fund LP
Inventors:
Julian S. Northen, John Mykytiuk, Gillian Moore
Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
Type:
Grant
Filed:
October 12, 2021
Date of Patent:
March 26, 2024
Assignee:
MERCK PATENT GMBH
Inventors:
Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis
Abstract: A curative system comprising a combination of adipic acid dihydrazide and/or isophthalic dihydrazide and a clathrate in which the guest compound of the clathrate comprises an imidazole, an imidazoline or diazabicycloalkanes (DBCA).
Type:
Grant
Filed:
August 30, 2019
Date of Patent:
March 26, 2024
Assignee:
HEXCEL COMPOSITES LIMITED
Inventors:
Christopher Robert Mason, Nicholas Verge
Abstract: A conditioning process that is employed with a high selectivity catalyst (HSC) during an initial phase (i.e., start-up) of the epoxidation process is provided. The HSC conditioning process of the present disclosure ensures that the heat release from a catalyst bed containing an HSC during a start-up operation is less than 2000 kJ/Kgcat·hr. The HSC containing catalyst bed that has been conditioned by the process of the present disclosure exhibits improved performance (i.e., EO selectivity) and reduced hot spots.
Abstract: An 2-[9-(2-hydroxypyridin-3-yl)-1,8-dioxo-1,2,3,4,5,-6,7,8,9,10-decahydroacridin-10-yl]-acetate compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
November 2, 2023
Date of Patent:
March 19, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
Abstract: A 12-bromo-2,16-dioxapentacyclo[7.7.5.01,21.03,8.010,15]henicosa3(8),10,12,14-tetraene-7,20-dione compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
October 17, 2023
Date of Patent:
March 19, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.
Type:
Grant
Filed:
April 7, 2022
Date of Patent:
March 19, 2024
Assignee:
Siemens Healthcare Diagnostics Inc.
Inventors:
Anand Natrajan, David Sharpe, Qingping Jiang, David Wen
Abstract: The present invention relates to novel use of koumine, an alkaloid monomer from Gelsemium elegans Benth., or a pharmaceutically acceptable salt thereof, and more particularly to use of koumine or its pharmaceutically acceptable salt in the preparation of a medicament for the treatment of inflammatory bowel disease.
Abstract: The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.
Type:
Grant
Filed:
November 17, 2021
Date of Patent:
March 12, 2024
Assignee:
GENENTECH, INC.
Inventors:
Lin Pan, Dorothy Sze-Wing Cheung, Jeffrey Mark Harris, Indiana Strombom
Abstract: An 9-(2-hydroxypyridin-3-yl)-10-(2-hydroxyethyl)-3,6-diphenyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
October 31, 2023
Date of Patent:
March 12, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed